BSX Boston Scientific

Q3 2025 10-Q

Filed: Nov 3, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Boston Scientific (BSX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 3, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• No quarterly revenue or YoY change figures disclosed in MD&A section provided
• Restructuring charges related to severance, facility closures, product line transfers including ACURATE neo2 and ACURATE Prime discontinuation

+3 more insights

Risk Factors

• No new or updated risk factors disclosed; risk section unchanged from most recent 10-K
• Legal/compliance risk: multiple directors and officers initiated Rule 10b5-1 trading plans for stock sales through 2026-2027

+2 more insights

Quarterly Financial Summary
XBRL

Revenue

$5.1B

▲ +20.3% YoY▲ +0.1% QoQ

Net Income

$755M

▲ +61.0% YoY▼ -5.3% QoQ

Gross Margin

69.9%

▲ +112bp YoY▲ +231bp QoQ

Operating Margin

20.7%

▲ +328bp YoY▲ +451bp QoQ

Net Margin

14.9%

▲ +377bp YoY▼ -84bp QoQ

ROE

3.2%

Total Assets

$42.7B

EPS (Diluted)

$0.51

▲ +59.4% YoY▼ -3.8% QoQ

Operating Cash Flow

$1.3B

▲ +34.0% YoY▲ +4.4% QoQ

Source: XBRL data from Boston Scientific Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Boston Scientific Quarterly Reports

Q2 2025 10-Q

Q1 2025 10-Q

Get deeper insights on Boston Scientific

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.